title: Improving Outcomes for Patients With Diabetic Macular Edema.
abstract: Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data.
authors.forename: Carmen A
authors.initials: CA
authors.lastname: Puliafito
authors.forename: Pravin U
authors.initials: PU
authors.lastname: Dugel
authors.forename: Scott W
authors.initials: SW
authors.lastname: Cousins
authors.forename: Kirk H
authors.initials: KH
authors.lastname: Packo
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Eaton
authors.forename: Richard K
authors.initials: RK
authors.lastname: Parrish
authors.forename: Szilárd
authors.initials: S
authors.lastname: Kiss
authors.forename: Elias
authors.initials: E
authors.lastname: Reichel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D017075:Laser Coagulation; D008055:Lipids / Q000097:blood; D008269:Macular Edema / Q000175:diagnosis / Q000628:therapy*; D018579:Patient Selection; D012307:Risk Factors; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D001786:Blood Glucose; D005938:Glucocorticoids; D008055:Lipids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A